Table 3 Parenteral or oral administration of vorinostat inhibits growth of a variety of tumours in rodents

From: Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor

Parenteral administration

Oral administration

Prostate cancer (CWR22 xenograft)

Breast adenocarcinoma (N-methylnitrosourea-induced)

Leukaemia (acute promyelocytic leukaemia transgenic)

Lung tumours (tobacco-specific nitrosamine-induced)

Lymphoma (mantle cell, Eμ-myc transgenic)

 

Glioma (F98 cells)

 
Back to article page